Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Summary
    VLA   FR0004056851


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Valneva : stock slumps after Britain ends COVID vaccine deal

09/13/2021 | 02:05am EDT
FILE PHOTO: A woman holds a medical syringe and a small bottle labelled

PARIS, Sept 13 (Reuters) - Valneva shares plunged 35% on Monday after the French drugmaker said the British government had ended a 1.4 billion euro ($1.65 billion) COVID-19 vaccine supply deal.

The British government "alleged that the company is in breach of its obligations under the supply agreement, but the company strenuously denies this," Valneva said in a statement.

Valneva's COVID-19 vaccine candidate VLA 2001 relies on inactivated virus, similar to flu vaccines, and is seen by some as having the potential to win over people wary of some which use new mRNA technology.

It had signed a deal with Britain for up to 190 million doses by 2025 in a transaction worth potentially up to 1.4 billion euros.

"Valneva has worked tirelessly, and to its best efforts, on the collaboration ... including investing significant resources and effort," the company added.

A spokesman for Prime Minister Boris Johnson said ending the Valneva deal would have no impact on vaccine supply in Britain.

"This is an ongoing commercial issue so I am slightly restricted in what I can say," the spokesman said, when asked why the deal had been cancelled.

"MHRA (Medicines and Healthcare products Regulatory Agency) have not approved the Valneva vaccine. The comments from the company will not have any impact on our vaccine supply and did not form any part of our vaccine rollout in autumn and winter," the spokesman told reporters.

Valneva, whose shares are still up by around 50% since the start of 2021, said it was still continuing its development plan for VLA 2001.

"Valneva believes that initial approval for VLA2001 could be granted in late 2021", it added.

This is not the first COVID-19 setback for Valneva after the European Commission said in April it had not met conditions to supply the bloc with its vaccine candidate.

In July, however, Valneva said talks with Brussels were still ongoing.

The French government has come under fire, particularly when shots were rare, for failing to secure doses from a domestic producer, after other French groups such as Sanofi or the Pasteur Institute ran into difficulties in producing a vaccine. ($1 = 0.8487 euros) (Reporting by Sudip Kar-Gupta, Benoit Van Overstraeten, Sarah White in Paris and Kylie MacLellan in London; Writing by Sudip Kar-Gupta and Ingrid Melander; Editing by Ana Nicolaci da Costa, Mark Potter and Alexander Smith)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
SANOFI 0.61% 82.73 Real-time Quote.4.49%
VALNEVA SE 9.59% 13.25 Real-time Quote.56.00%
All news about VALNEVA SE
09/17VALNEVA : Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivate..
09/15VALNEVA : UK Health Secretary Rules Out Approval for Valneva COVID-19 Vaccine
09/14GLOBAL MARKETS LIVE : Intuit, Walmart, Qualcomm, Alibaba, Oracle...
09/14VACCINE MINISTER : 'We have a right to cancel' the 140m Valneva jabs order
09/14UK MINISTER : Regulator concern sank deal for Valneva shot
09/14VALNEVA : UK Minister Notes 'Commercial Sensitivities' in Terminated Valneva Vaccine Deal
09/14VALNEVA : Completes Enrollment of Elderly Patients in Phase 3 Trial of COVID-19 Vaccine Ca..
09/14Uk vaccines minister zahawi says we have a right to cancel the valneva vaccine and that..
09/14VALNEVA : Concludes Enrollment Of Elderly In Late-Stage COVID-19 Jab Study
09/14VALNEVA : Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivate..
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Sales 2021 301 M 353 M 353 M
Net income 2021 -102 M -119 M -119 M
Net cash 2021 80,7 M 94,6 M 94,6 M
P/E ratio 2021 -11,6x
Yield 2021 -
Capitalization 1 208 M 1 415 M 1 417 M
EV / Sales 2021 3,74x
EV / Sales 2022 2,03x
Nbr of Employees 700
Free-Float 71,4%
Duration : Period :
Valneva SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 12,09 €
Average target price 13,80 €
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Charles Marie Grimaud Co-President & Chief Business Officer
Peter Buhler Chief Financial Officer & Director
FrÚdÚric Grimaud Chairman-Supervisory Board
Michael M÷hlen Vice President-Technical Development
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE56.00%1 415
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021